How Novo Nordisk Misjudged the US Market for Its Weight Loss Breakthrough
Novo Nordisk shook the pharmaceutical world with its weight loss treatment Wegovy, a breakthrough that generated billions in profit. But according to former employees, the company misread the U.S. market, overlooking early warnings and failing to prepare for demand, letting competitors take advantage.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
